In early December, CRISPR-Cas9 gene editing therapy was approved by the Food and Drug Administration for the treatment of sickle cell in patients ages 12 and up. It’s the first FDA approval for the gene-editing therapy, whose creators won the Nobel Prize in chemistry in 2020.
Education, workplace culture key to addressing oncology nursing shortage healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Education, workplace culture key to addressing oncology nursing shortage healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Treatment with exagamglogene autotemcel conferred clinically meaningful increases in fetal hemoglobin and total hemoglobin levels among patients with beta-thalassemia and sickle cell disease, results of two pivotal studies showed. The latest follow-up data from the CLIMB THAL-111 and CLIMB-SCD-121 trials — presented at American Society for Gene & Cell Therapy Annual Meeting —